The FDA approved Ionis Pharmaceuticals' Zanvastro for Alexander disease, while Summit shares rose following positive survival data for its lung cancer drug compared to Keytruda. However, Ultragenyx stock plummeted after its Phase 3 Angelman syndrome drug failed a critical trial, prompting potential cost cuts. Additionally, Oura filed for an IPO targeting a $16 billion valuation, and GSK struck a cancer deal with Hutchmed worth up to $1.3 billion.
01Market mover
FDA Approves First Ever Treatment for Alexander Disease
Securing four distinct regulatory priority designations for a rare-disease oligonucleotide validates Ionis's targeted RNA-targeting model by guaranteeing market exclusivity alongside accelerated commercialization.
The US Food and Drug Administration approved Zanvastro injection as the first treatment for Alexander disease in pediatric and adult patients. Developed by Ionis Pharmaceuticals, the antisense oligonucleotide works by reducing the production of the abnormal glial fibrillary acidic protein that drives the rare neurological disorder. The agency evaluated in a clinical study of 49 patients aged two years and older, alongside an open-label substudy of four younger patients. Patients aged five years and older treated with the drug showed significantly better walking speed at 61 weeks compared to untreated controls. The approval was granted after the therapy received orphan drug, fast track, breakthrough therapy, and rare pediatric disease designations.
Clinical Study Enrollment by Age Group (Patients)
The primary clinical study enrolled 49 patients, supplemented by 4 younger patients.
GSK Licenses Hutchmed Cancer Drug for $110 Million Upfront
Outsourcing early-stage trial execution to a Chinese biotech lets GSK acquire dual-inhibitor oncology assets without incurring Western preclinical development costs before clinical proof of concept.
GSK agreed to pay Hutchmed $110 million upfront and up to roughly $1.19 billion in potential milestone payments for rights to the early-stage cancer drug HMPL-A830. The therapy is an antibody-targeted conjugate designed to block both EGFR and KRAS cancer drivers, and it is slated to enter this year. Under the agreement, Hutchmed will oversee Phase 1 studies before GSK takes over global development and commercialization outside of mainland China, Hong Kong, Macau, and Taiwan. The targets solid tumors such as colorectal, pancreatic, and lung cancers that frequently lack durable treatment . The transaction expands GSK's pipeline through a partnership with a China-based biotechnology developer.
Ultragenyx Angelman syndrome drug fails late-stage trial
When placebo controls invalidate early rare-disease signals, commercial biotechs lose the primary pipeline bridge required to turn current ultra-rare revenues into company-wide profitability.
Ultragenyx lost almost half its value after an experimental Angelman syndrome treatment missed all primary and secondary endpoints in a late-stage trial. The drug, known as GTX-102 or apazunersen, showed no difference compared to control groups in the Aspire study, forcing the company to evaluate the program for potential termination. Ultragenyx now plans to implement significant expense reductions as it shifts its focus toward approved products and profitability in 2027. The failure erased the therapy's projected peak sales of $1.8 billion or more, leaving upcoming treatments like the Sanfilippo syndrome candidate UX111 with substantially lower peak estimates of $120 million to $240 million. Ionis Pharmaceuticals shares fell 4% in early trading following the news, as the setback cast a shadow over similar antisense therapies in development.
AbbVie Announces Phase 3 Win for Multiple Myeloma Drug Etentamig
Translating etentamig's progression-free survival benefit into global regulatory approvals would give AbbVie a targeted oncology therapy capable of offsetting patent cliff revenue losses in immunology.
AbbVie reported that its multiple myeloma drug etentamig cut the risk of disease progression or death by 60% compared to standard therapies in a . The randomized study, named Cervino, evaluated 393 patients with relapsed or refractory multiple myeloma who had received at least two prior lines of therapy. Patients treated with monthly intravenous etentamig achieved a 74% objective response rate, compared with 45.7% for the control arm receiving standard available therapies. The 12-month overall survival rate reached 87.9% for the drug group against 72% for standard care, though the prespecified boundary for overall survival had not been crossed at the data cutoff. Etentamig also demonstrated a manageable safety profile with a 28.3% incidence of mostly low-grade cytokine release syndrome. Following the positive interim analysis from the independent data monitoring committee, AbbVie plans to present the full findings at the International Myeloma Society Annual Meeting and discuss regulatory next steps with global authorities.
Cervino Trial Response and Survival Rates (%)
Etentamig significantly outperformed standard therapies across response and survival metrics.
Summit and Akeso Confirm Survival Benefit in Phase 3 Lung Cancer Trial
Demonstrating an overall survival advantage over a reigning checkpoint inhibitor validates dual-targeting bispecific antibodies as a viable mechanism to displace established single-pathway oncology blockbusters.
Ivonescimab extended overall survival compared with Merck & Co.'s Keytruda in a of Chinese patients with non-small cell lung cancer, according to developers Akeso and its U.S. licensee Summit Therapeutics. The bispecific antibody targets both PD-1 and VEGF, positioning it to challenge established immunotherapies that reshaped care over the last decade. While the Food and Drug Administration will require data from a global trial expected in 2028 for U.S. approval, the latest survival findings derisk separate combination studies evaluating the drug alongside chemotherapy against Keytruda and chemo. Full results are slated for presentation at an upcoming lung cancer conference later this month. Summit shares climbed as much as 14% during Thursday morning trading following the announcement.
Subscription-led hardware valuations rely heavily on user trust in proprietary wellness algorithms, making claims of synthetic sleep tracking a direct threat to recurring revenue durability.
TechCrunch reports that Oura has filed to go public, revealing a jump to $1.2 billion for the nine-month period ending June 30, up from $697 million during the same timeframe last year. The smart ring maker is reportedly seeking to raise $3 billion in its public offering at a of $16 billion, following an $11 billion valuation in October of last year. Oura generated $500 million in revenue in 2024 and roughly $1 billion in 2025, while selling 3.6 million rings over the past year to reach approximately 5 million paid members. Those subscribers maintain an 85% weighted-average 12-month retention rate for the $350 to $400 devices. The company confidentially filed for an in May after being founded in Finland in 2013. That public offering arrives alongside a proposed class action lawsuit accusing Oura of misleading users about the accuracy of its sleep tracking capabilities. The litigation alleges the rings rely on -generated estimates rather than direct physiological signals to determine sleep stages, an accusation the company disputes.
Nine-Month Revenue ($M)
Oura's nine-month revenue grew from $697 million to $1.2 billion.
Gene-Edited Pig Kidney Recipients Successfully Receive Human Organs
Proving that eGenesis xenografts avoid cross-reactive antibody sensitization establishes gene-edited animal organs as viable temporary bridging therapies, opening a commercial pathway prior to achieving permanent graft survival.
statnews.com reports that two early recipients of gene-edited pig kidneys from eGenesis have successfully transitioned to human organ transplants. Doctors removed the initial xenografts and placed both patients back on dialysis for months before human donors became available. The bridging success answers a key clinical question about whether interspecies animal transplants provoke antibodies that would complicate subsequent human-to-human procedures. Xenotransplantation projects are driven by chronic shortages of human organs that leave many patients waiting indefinitely. The two patients spent months off dialysis before receiving their human organs.
Strong clinical results and a high profile IPO filing demonstrate robust healthcare innovation, but major trial failures highlight the severe downside risk in biotech. The key question is whether cost reductions at struggling firms will drag down broader sector sentiment.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.